Emergent BioSolutions Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on March 17, 2017, covering events that occurred on March 16, 2017. The filing details the entry into material definitive agreements with the Biomedical Advanced Research and Development Authority (BARDA) regarding anthrax vaccine procurement and development.
Key Financial Metrics and Contract Values
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for a specific reporting period. Instead, it discloses the following contract values:
- New BioThrax Contract: Valued at $100 million for delivery to the Strategic National Stockpile over a two-year period.
- NuThrax Contract Amendment: The total potential contract value was reduced to up to $1.5 billion, down from a previously disclosed $1.6 billion.
Material Changes and Contract Details
Two significant contractual developments were reported:
- BioThrax Procurement: Emergent Biodefense Operations Lansing LLC entered a new contract for the delivery of BioThrax (Anthrax Vaccine Adsorbed). The contract includes standard government terms allowing the government to terminate for convenience, suspend work, or audit costs.
- NuThrax Modification: Emergent Product Development Gaithersburg Inc. amended its existing contract for NuThrax. Key changes include:
- Increasing the base period delivery from 2 million to 3 million doses.
- Implementing a commensurate reduction in the dose price for initial deliveries.
- Reducing the purchase price for option period doses by $100 million.
Outlook, Risks, and Contingencies
The filing highlights specific risks inherent in government contracts, including the government's right to terminate the BioThrax contract at any time for its convenience or to suspend work. Additionally, the government retains the right to audit costs and require reimbursement for costs deemed unallowable under the Federal Acquisition Regulation. The filing notes that the full contract texts will be available as exhibits to the Form 10-Q for the quarter ending March 31, 2017.
Key Facts for Investor Verification
- Verify the impact of the $100 million price reduction on the NuThrax contract on future revenue recognition.
- Confirm the specific pricing per dose for the increased 3 million dose base period of NuThrax.
- Review the upcoming Form 10-Q for the full text of the BioThrax and NuThrax agreements to assess termination and audit clauses.
- Monitor the two-year performance period for the $100 million BioThrax delivery contract.